FY2020 Earnings Estimate for Regeneron Pharmaceuticals, Inc. (REGN) Issued By SunTrust Banks

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at SunTrust Banks lifted their FY2020 earnings per share estimates for shares of Regeneron Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst Y. Suneja now anticipates that the biopharmaceutical company will post earnings of $19.07 per share for the year, up from their prior estimate of $18.97. SunTrust Banks has a “Hold” rating and a $435.00 price objective on the stock.

A number of other brokerages have also recently commented on REGN. Bank of America Corporation restated a “buy” rating and issued a $593.00 price target (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. BMO Capital Markets reaffirmed a “market perform” rating and issued a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Barclays PLC reaffirmed an “equal weight” rating and issued a $450.00 price objective (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a research note on Saturday, July 22nd. Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $575.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 7th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $481.49.

ILLEGAL ACTIVITY WARNING: “FY2020 Earnings Estimate for Regeneron Pharmaceuticals, Inc. (REGN) Issued By SunTrust Banks” was originally reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/14/fy2020-earnings-estimate-for-regeneron-pharmaceuticals-inc-regn-issued-by-suntrust-banks.html.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $8.52 on Monday, reaching $385.10. The company’s stock had a trading volume of 532,547 shares, compared to its average volume of 902,722. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The stock has a market capitalization of $43,346.87, a PE ratio of 35.03, a price-to-earnings-growth ratio of 1.56 and a beta of 1.56. Regeneron Pharmaceuticals has a fifty-two week low of $340.09 and a fifty-two week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.13 earnings per share.

A number of hedge funds and other institutional investors have recently made changes to their positions in REGN. AQR Capital Management LLC boosted its position in Regeneron Pharmaceuticals by 201.4% during the 1st quarter. AQR Capital Management LLC now owns 8,805 shares of the biopharmaceutical company’s stock valued at $3,412,000 after acquiring an additional 5,884 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $233,000. Fisher Asset Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 75.1% in the 2nd quarter. Fisher Asset Management LLC now owns 1,411 shares of the biopharmaceutical company’s stock worth $693,000 after purchasing an additional 605 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $642,000. Finally, Wendell David Associates Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $204,000. 67.80% of the stock is currently owned by institutional investors and hedge funds.

In other Regeneron Pharmaceuticals news, SVP Robert E. Landry sold 468 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $476.45, for a total transaction of $222,978.60. Following the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at approximately $4,335,218.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the sale, the director now directly owns 11,000 shares in the company, valued at approximately $4,950,000. The disclosure for this sale can be found here. Insiders have sold a total of 88,942 shares of company stock worth $42,064,076 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply